Genentech will permanently cut 103 jobs across multiple divisions, with the South San Francisco biotech giant confirming the reductions will hit its research and early development arm known as gRED.
The layoffs take effect July 29 at the company’s headquarters at 1 DNA Way, according to a filing with California employment officials. This marks yet another downsizing at the pioneering firm, which touts itself as the original biotechnology company and anchors Roche’s U.S. pharmaceutical operations.
Founded in 1976, Genentech employs roughly 12,100 people nationwide. The latest cuts represent a small fraction of that workforce, but they continue a pattern of restructuring that has touched senior leadership.
In June, three vice presidents left the company as part of the gRED reorganization. Vishva Dixit, Man-Wah Tan, and Todd McDevitt were among those dismissed, according to Fierce Biotech. Internal communications obtained by Endpoints News indicated Genentech would shutter its physiological chemistry and infectious disease teams entirely while trimming other research groups.
Stephanie Huang, senior director of science communications, framed the moves as targeted adjustments rather than broad retreat. She noted that hiring continues across Genentech, including within gRED, with recruitment priorities shaped by the capabilities and scientific expertise needed to advance the company’s drug pipeline.
Huang acknowledged the human cost of the restructuring while arguing that constant adaptation remains necessary in a fast-moving industry. The company plans to keep evaluating its organizational structure against shifting market and scientific demands.
The layoffs arrive as biotech firms nationwide grapple with tighter funding conditions and pressure to streamline research spending. Genentech’s continued hiring alongside the cuts suggests a strategic reshuffling rather than wholesale contraction, but the coming months will reveal whether this balancing act stabilizes the company’s research enterprise or signals deeper changes ahead.
